Intra Cellular Therapies traded at $53.57 this Friday August 12th, decreasing $3.45 or 6.05 percent since the previous trading session. Looking back, over the last four weeks, Intra Cellular Therapies lost 0.34 percent. Over the last 12 months, its price rose by 84.53 percent. Looking ahead, we forecast Intra Cellular Therapies to be priced at 58.33 by the end of this quarter and at 53.61 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
53.57
Daily Change
-6.05%
Yearly
84.53%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Acadia Pharmaceuticals 16.40 0.66 4.19% -6.71%
ALKERMES 26.15 0.68 2.67% -9.04%
Aptinyx Inc 0.41 -0.19 -32.33% -83.15%
BioCryst Pharmaceuticals 14.64 0.27 1.88% -9.35%
Biogen 220.99 2.77 1.27% -35.43%
Bristol-Myers Squibb 75.57 1.11 1.49% 11.94%
Cytokinetics 50.30 0.83 1.68% 56.45%
Esperion Therapeutics 6.70 0.06 0.90% -51.83%
Gilead Sciences 62.96 0.51 0.82% -11.52%
Halozyme Therapeutics 43.14 -0.22 -0.51% 4.03%
Intra Cellular Therapies 53.57 -3.45 -6.05% 84.53%
Jazz Pharmaceuticals 157.08 2.83 1.83% 10.50%
J&J 165.30 -1.84 -1.10% -6.21%
Marinus Pharmaceuticals 5.80 0.03 0.52% -52.50%
Neurocrine Biosciences 105.63 0.75 0.72% 18.53%
Minerva Neurosciences 3.29 -0.10 -2.95% 94.67%
Nektar Therapeutics 5.14 0.19 3.84% -64.03%
Novartis 85.68 0.10 0.12% -8.69%
Prothena 32.19 0.91 2.91% -44.93%
RedHill Biopharma 1.06 0.10 10.42% -85.07%
Supernus Pharmaceuticals 32.79 1.53 4.89% 32.54%
United Therapeutics 217.10 -3.31 -1.50% 7.15%
Vanda Pharmaceuticals 10.41 0.11 1.07% -36.79%

Indexes Price Day Year
USND 13047 267.27 2.09% -11.98%
US2000 2017 41.36 2.09% -9.29%

Intra Cellular Therapies
Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company that is focused on the discovery, clinical development, and commercialization of small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company offers CAPLYTA for the treatment of schizophrenia as is typical for antipsychotics. Its lumateperone bipolar depression clinical program consists of three monotherapy studies and one adjunctive study. The Company also initiated its third monotherapy Phase III study, Study 403, evaluating lumateperone as monotherapy in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder.